BioVector® CHLA-90 人神经母细胞瘤细胞系 / BioVector® CHLA-90 Human Neuroblastoma Cell Line

通用定义 / General Definition:

BioVector® CHLA-90 是一种源自人类神经母细胞瘤 (Neuroblastoma) 的细胞系。该细胞系建立于一名接受过诱导化疗、手术及自体骨髓移植后复发的患儿。CHLA-90 在分子生物学上非常具有代表性，它具有 MYCN 基因扩增 且携带 TP53 基因突变。在神经母细胞瘤研究中，这种“双重打击”（MYCN 扩增 + TP53 功能缺失）通常与极高的耐药性和极差的预后相关。因此，该细胞系是研究晚期复发性肿瘤耐药机制、细胞凋亡逃逸以及筛选新一代抗肿瘤药物的关键工具。

BioVector® CHLA-90 is a human cell line derived from Neuroblastoma. It was established from a patient who relapsed following intensive induction chemotherapy, surgery, and autologous bone marrow transplantation. CHLA-90 is molecularly significant as it features MYCN gene amplification combined with a TP53 gene mutation. In neuroblastoma research, this "double hit" (MYCN amplification + loss of TP53 function) is associated with high-level drug resistance and poor clinical outcomes. Consequently, this line is a pivotal tool for studying resistance mechanisms in advanced relapsed tumors, evasion of apoptosis, and screening next-generation anti-cancer therapeutics.

BioVector® CHLA-90 技术说明书 (Technical Datasheet)

中文版说明书 (Chinese Datasheet)

1. 产品基本信息

• 产品名称： BioVector® CHLA-90 人神经母细胞瘤细胞

• 组织来源： 转移灶/复发肿瘤组织

• 分子特征：MYCN 扩增；TP53 突变；通常表现为对 p53 依赖性凋亡诱导药物（如某些传统化疗药）的强烈耐受。

• 生长特性： 贴壁生长。

• 细胞形态： 呈现典型的小圆细胞形态，胞浆极少，有时可见短小的神经突起。

2. 培养条件

• 基础培养基： BioVector® IMDM 或 DMEM/F-12 (1:1)。

• 血清添加： 10% - 20% BioVector® 优质胎牛血清 (FBS)。

• 补充因子： 建议添加 1x ITS (胰岛素-转移蛋白-硒) 和 L-谷氨酰胺，以增强复发细胞系的稳健性。

• 培养环境： 37 摄氏度，5% $CO_2$。

• 传代比例： 1:2 至 1:4；该细胞生长速度适中。

3. 细胞应用

• 凋亡逃逸研究： 探索 TP53 突变如何影响肿瘤细胞对 DNA 损伤反应的调节。

• 耐药筛选： 评估新型小分子抑制剂（如 ALK 抑制剂、PARP 抑制剂或免疫代谢药物）在极端耐药背景下的效能。

• 转录组分析： 研究 MYCN 与突变型 p53 在促进肿瘤演进中的协同作用。

4. 注意事项

• 血清质量敏感性： 鉴于该细胞系源自多次治疗后的样本，其对血清质量较为敏感，建议使用经过验证的同批次优质胎牛血清。

• 生长形态监控： 细胞在低汇合度下可能生长较慢，建议在接种时保持较高的起始密度（约 $5 \times 10^4$ cells/$cm^2$）。

English Datasheet

1. General Product Information

• Product Name: BioVector® CHLA-90 Human Neuroblastoma Cell Line

• Source: Metastatic site/Relapsed tumor tissue

• Molecular Profile:MYCN Amplified; TP53 Mutated; typically exhibits profound resistance to drugs that rely on p53-mediated apoptosis.

• Growth Properties: Adherent.

• Morphology: Small round cells with minimal cytoplasm; may display occasional short neurite-like processes.

2. Culture Conditions

• Basal Medium: BioVector® IMDM or DMEM/F-12 (1:1).

• Serum Supplement: 10% - 20% BioVector® Fetal Bovine Serum (FBS).

• Supplements: Supplementation with 1x ITS (Insulin-Transferrin-Selenium) and L-Glutamine is recommended to support the robustness of this relapsed-derived line.

• Incubation: 37°C, 5% $CO_2$.

• Subculturing: 1:2 to 1:4 ratio; growth rates are moderate.

3. Applications

• Apoptosis Evasion Studies: Investigating how TP53 mutations alter the cellular response to DNA-damaging agents.

• Drug Discovery: Evaluating the efficacy of novel small molecules (e.g., ALK, PARP, or Aurora Kinase inhibitors) within a highly resistant genetic background.

• Functional Genomics: Studying the cooperativity between MYCN overexpression and p53 dysfunction in driving neuroblastoma progression.

4. Key Usage Notes

• Serum Sensitivity: As a late-stage relapse line, CHLA-90 is sensitive to serum variability; BioVector® recommends using high-quality, heat-inactivated FBS from a consistent lot.

• Seeding Density: Cells may exhibit a lag phase if seeded too sparsely. Maintaining an optimal seeding density (approx. $5 \times 10^4$ cells/$cm^2$) is crucial for consistent culture expansion.

注意 / Note: BioVector® CHLA-90 应在生物安全二级 (BSL-2) 条件下操作。由于携带 TP53 突变，该细胞系在基因组稳定性方面可能较差，建议在实验关键节点进行 STR 鉴定及核型分析。

BioVector® CHLA-90 should be handled under Biosafety Level 2 (BSL-2) conditions. Due to the TP53 mutation, the line may possess inherent genomic instability; BioVector® recommends routine STR profiling and karyotypic analysis during long-term culture.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net